Cite
Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer
MLA
Astrid Kramer, et al. “Early Evaluation of the Effectiveness and Cost-Effectiveness of CtDNA-Guided Selection for Adjuvant Chemotherapy in Stage II Colon Cancer.” Therapeutic Advances in Medical Oncology, vol. 16, Aug. 2024. EBSCOhost, https://doi.org/10.1177/17588359241266164.
APA
Astrid Kramer, Marjolein J. E. Greuter, Suzanna J. Schraa, Geraldine R. Vink, Jillian Phallen, Victor E. Velculescu, Gerrit A. Meijer, Daan van den Broek, Miriam Koopman, Jeanine M. L. Roodhart, Remond J. A. Fijneman, Valesca P. Retèl, & Veerle M. H. Coupé. (2024). Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241266164
Chicago
Astrid Kramer, Marjolein J. E. Greuter, Suzanna J. Schraa, Geraldine R. Vink, Jillian Phallen, Victor E. Velculescu, Gerrit A. Meijer, et al. 2024. “Early Evaluation of the Effectiveness and Cost-Effectiveness of CtDNA-Guided Selection for Adjuvant Chemotherapy in Stage II Colon Cancer.” Therapeutic Advances in Medical Oncology 16 (August). doi:10.1177/17588359241266164.